Karyopharm Therapeutics
KPTI
KPTI
91 hedge funds and large institutions have $49.2M invested in Karyopharm Therapeutics in 2024 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 20 increasing their positions, 30 reducing their positions, and 31 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
less ownership
Funds ownership: →
less capital invested
Capital invested by funds: $ → $
less funds holding
Funds holding: →
33% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 30
71% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 31
Holders
91
Holding in Top 10
–
Calls
$929K
Puts
$68K
Top Buyers
| 1 | +$658K | |
| 2 | +$465K | |
| 3 | +$403K | |
| 4 |
D.E. Shaw & Co
New York
|
+$169K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$144K |
Top Sellers
| 1 | -$1.24M | |
| 2 | -$1.12M | |
| 3 | -$792K | |
| 4 |
Millennium Management
New York
|
-$695K |
| 5 |
Barclays
London,
United Kingdom
|
-$641K |